| Literature DB >> 31397910 |
Michael A Elliott1, Henrique Malvar2, Lindsey L Maassel1, Jon Campbell2, Harish Kulkarni2, Irina Spiridonova2, Noelle Sophy2, Jay Beavers2, Ann Paradiso2, Chuck Needham2, Jamie Rifley2, Maggie Duffield2, Jeremy Crawford2, Becky Wood1, Emily J Cox3, James M Scanlan4.
Abstract
BACKGROUND: Our pilot study tested the feasibility and performance of an eye-controlled power wheelchair for amyotrophic lateral sclerosis (ALS) patients.Entities:
Keywords: ALS; eye-controlled; mobility; power wheelchair; quality of life
Mesh:
Year: 2019 PMID: 31397910 PMCID: PMC6851551 DOI: 10.1002/mus.26655
Source DB: PubMed Journal: Muscle Nerve ISSN: 0148-639X Impact factor: 3.217
Demographics and clinical characteristics of participants
| Subject | Age (y) | Sex | Height (cm) | Weight (kg) | Disease duration (mos) | Region of onset | ALS FRS‐R | El Escorial Criteria | FVC (%) | Glasses | WCD vs AMB |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 75 | M | 180.3 | 79.8 | 35 | RLE | 33 | CP | 90 | No | WCD |
| 2 | 56 | M | 203.2 | 86.2 | 14 | LUE | 35 | CD | 75 | No | AMB |
| 3 | 57 | M | 189.2 | 85.7 | 84 | RUE | 32 | CD | 65 | Yes | WCD |
| 4 | 69 | M | 160.0 | 67.2 | 46 | LLE | 38 | CD | 71 | Yes | WCD |
| 5 | 68 | F | 162.6 | 68 | 34 | BLE | 21 | CD | 53 | No | WCD |
| 6 | 73 | F | 152.4 | 126 | 19 | RLE | 42 | CP | 84 | Yes | AMB |
| 7 | 35 | F | 160.0 | 61.7 | 22 | RUE | 35 | CD | 90 | Yes | AMB |
| 8 | 73 | M | 168.9 | 154 | 29 | RLE | 40 | CP | 74 | Yes | AMB |
| 9 | 63 | M | 165.1 | 55.2 | 16 | LUE | 25 | CD | 59 | Yes | AMB |
| 10 | 71 | M | 177.8 | 104.6 | 39 | Bulbar | 29 | CP | 74 | No | AMB |
| 11 | 63 | M | 177.8 | 59.9 | 48 | BUE | 34 | CPLS | 64 | No | AMB |
| 12 | 47 | M | 182.9 | 90.7 | unk | RLE | 29 | CP | 50.3 | No | WCD |
| Means | 62.5 | 75% M | 173.3 | 86.6 | 35 | 32.8 | 70.8 | 50% |
Abbreviations: CD, clinically definite; CP, clinically probable; CPLS, clinically probable laboratory‐supported; F, female; M, male; unk, unknown.
Participant task completion: Time in seconds
| Tasks | Completion | Range | Tasks complete |
|---|---|---|---|
| Stop on command | 1.1 (.3) | 1‐2 | 12 |
| Start on command | 1.0 (0) | 1‐1 | 12 |
| Negotiate obstacles | 97% N/A | 0‐0 | 11 |
| 90° turn | 6.1 (5.4) | 2‐30 | 11 |
| 135° turn | 7.2 (2.6) | 4‐13 | 11 |
| 180° turn | 13.8 (5.7) | 5‐43 | 11 |
| Backup short | 13.9 (6.2) | 6‐34 | 12 |
| Backup long | 23.6 (8.9) | 12‐56 | 12 |
| Overall time (s) | 235.6 (38.6) | 194‐373 | N/A |
Note: Mean (SD) time to successfully complete wheelchair tasks. Tasks complete indicates the number of participants who successfully completed the task across all three trials.
Self‐Reported Responsivity Experience
| Experience measures | All participants | AMB | WCD |
|
|---|---|---|---|---|
| Stop | 4.4 | 4.7 | 4.0 | .064 |
| Start | 4.7 | 5.0 | 4.2 | .016 |
| Obstacles | 4.3 | 4.6 | 4.0 | .23 |
| 90° turn | 4.2 | 4.7 | 3.4 | .001 |
| 135° turn | 4.3 | 4.7 | 3.6 | .004 |
| 180° turn | 4.3 | 4.7 | 3.8 | .008 |
| Backup | 3.6 | 4.0 | 3.0 | .085 |
| Overall | 4.6 | 4.7 | 4.4 | .32 |
Note: Patient responses to wheelchair time trial. Data are presented as means.
Summary of participants comments from questionnaire
| Comment category | N | (%) |
|---|---|---|
| Want/need more practice | 6 | (50%) |
| Want screen changes (total) | 5 | (42%) |
| ‐Can't see where going | 2 | (17%) |
| ‐Want to lower or change screen angle | 2 | (17%) |
| ‐Want smaller screen icons | 2 | (17%) |
| ‐Hard to look where going | 1 | (8%) |
| ‐Want screen controls centrally located | 1 | (8%) |
| Want backup camera/backup difficult | 4 | (33%) |
| System is fun, excellent | 3 | (25%) |
| Want more control | 2 | (17%) |
| Want shadow outline of head on screen | 1 | (8%) |
| Want chair change to improve vision | 1 | (8%) |
| Want visual & auditory obstacle cues | 1 | (8%) |
Note: comments received from participant questionnaire.
While screen modifications were requested eight times, some patients suggested multiple changes, and the total number of patients asking for the specific screen changes listed here was five.